insulin human 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5003 11061-68-0

Description:

MoleculeDescription

Synonyms:

  • insulin (human)
  • insulin
  • insulin regular human
  • insulin susp isophane recombinant human
  • insulin susp isophane semisynthetic purified human
  • insulin zinc susp extended recombinant human
  • insulin zinc susp recombinant human
  • insulin zinc susp semisynthetic purified human
  • insulin human base
  • insulin human isophane
  • insulin human
  • insulin recombinant human
  • insulin human (genetical recombination)
  • humulin
  • insulin recombinant purified human
Insulin (51 aa, ~6 kDa) is encoded by the human INS gene. This protein is involved in the direct regulation of glucose metabolism.
  • Molecular weight: 5807.63
  • Formula: C257H383N65O77S6
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 2299.07
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
40 U P
40 U P
40 U P
40 U P
40 U P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 28, 1982 FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 919.29 11.02 587 34471 70737 50499329
Hypoglycaemia 882.50 11.02 516 34542 53065 50517001
Blood glucose decreased 385.29 11.02 207 34851 18004 50552062
Hyperglycaemia 273.63 11.02 216 34842 36189 50533877
Diabetes mellitus inadequate control 257.41 11.02 142 34916 13003 50557063
Diabetic ketoacidosis 212.18 11.02 140 34918 17732 50552334
Toothache 211.96 11.02 137 34921 16757 50553309
Pharyngitis 200.28 11.02 134 34924 17369 50552697
Blood glucose fluctuation 199.16 11.02 83 34975 4063 50566003
Glycosylated haemoglobin increased 197.88 11.02 111 34947 10495 50559571
Gait inability 137.25 11.02 148 34910 36879 50533187
Diabetic retinopathy 125.87 11.02 50 35008 2160 50567906
Hypoglycaemic coma 119.82 11.02 49 35009 2284 50567782
Blood glucose abnormal 103.64 11.02 62 34996 6610 50563456
Ketoacidosis 92.90 11.02 48 35010 3847 50566219
Anti-insulin antibody positive 89.32 11.02 19 35039 73 50569993
Wrong product administered 86.36 11.02 51 35007 5309 50564757
Insulin resistance 85.75 11.02 28 35030 680 50569386
Hyperkalaemia 80.45 11.02 130 34928 47959 50522107
Cardiac failure congestive 79.98 11.02 179 34879 84203 50485863
Drug intolerance 78.39 11.02 27 35031 219077 50350989
Contraindicated product administered 77.49 11.02 7 35051 148951 50421115
Joint swelling 75.26 11.02 38 35020 245248 50324818
Exposure during pregnancy 73.46 11.02 217 34841 120798 50449268
Product complaint 73.38 11.02 62 34996 11404 50558662
Off label use 73.20 11.02 136 34922 474290 50095776
Systemic lupus erythematosus 69.54 11.02 8 35050 140614 50429452
Hypoglycaemic unconsciousness 69.41 11.02 24 35034 698 50569368
Incorrect dose administered 67.90 11.02 121 34937 48293 50521773
Anti-insulin antibody increased 67.52 11.02 14 35044 46 50570020
Glossodynia 67.30 11.02 3 35055 115566 50454500
Pain 66.78 11.02 194 34864 578709 49991357
Fatigue 62.94 11.02 265 34793 707336 49862730
Completed suicide 61.61 11.02 9 35049 131880 50438186
Alopecia 60.09 11.02 49 35009 244998 50325068
Rheumatoid arthritis 59.72 11.02 33 35025 202517 50367549
Renal failure 57.96 11.02 184 34874 106449 50463617
Diabetic neuropathy 54.81 11.02 33 35025 3558 50566508
Product prescribing error 54.67 11.02 70 34988 20891 50549175
Infusion related reaction 53.91 11.02 25 35033 169532 50400534
Blindness 53.66 11.02 63 34995 17206 50552860
Abdominal discomfort 51.19 11.02 51 35007 231590 50338476
Lactic acidosis 50.18 11.02 86 34972 33269 50536797
Myocardial infarction 49.64 11.02 155 34903 88872 50481194
Therapeutic product effect decreased 48.22 11.02 17 35041 136033 50434033
Acute kidney injury 47.47 11.02 295 34763 227763 50342303
Hypoglycaemic seizure 46.81 11.02 16 35042 449 50569617
Coronary artery disease 46.52 11.02 78 34980 29648 50540418
Arthropathy 46.14 11.02 26 35032 157880 50412186
Retinopathy 44.20 11.02 26 35032 2686 50567380
Pericarditis 42.85 11.02 3 35055 78686 50491380
Rash 41.16 11.02 160 34898 437311 50132755
Discomfort 41.14 11.02 12 35046 108368 50461698
Expired product administered 40.53 11.02 32 35026 5350 50564716
Hypoaesthesia 40.42 11.02 185 34873 127072 50442994
Musculoskeletal stiffness 39.22 11.02 20 35038 128461 50441605
Dehydration 38.74 11.02 208 34850 152241 50417825
Product storage error 38.65 11.02 45 35013 12179 50557887
Medication error 38.07 11.02 80 34978 36024 50534042
Anti-insulin antibody 37.76 11.02 8 35050 30 50570036
Maternal exposure during pregnancy 37.26 11.02 213 34845 159565 50410501
Therapeutic product effect incomplete 34.97 11.02 10 35048 91505 50478561
Cerebrovascular accident 34.92 11.02 144 34914 94536 50475530
Increased insulin requirement 32.35 11.02 8 35050 67 50569999
Eye haemorrhage 31.98 11.02 32 35026 7303 50562763
Hepatic enzyme increased 31.77 11.02 29 35029 137351 50432715
Central nervous system injury 31.62 11.02 9 35049 135 50569931
Lower respiratory tract infection 31.41 11.02 140 34918 95061 50475005
Product use issue 30.65 11.02 35 35023 149440 50420626
Drug abuse 30.60 11.02 3 35055 59843 50510223
Drug ineffective 28.75 11.02 398 34660 818935 49751131
Chronic kidney disease 28.70 11.02 76 34982 39695 50530371
Sinusitis 26.99 11.02 48 35010 170510 50399556
Foetal exposure during pregnancy 26.97 11.02 59 34999 27300 50542766
Drug hypersensitivity 26.75 11.02 87 34971 250923 50319143
Type 1 diabetes mellitus 26.71 11.02 20 35038 3093 50566973
Multi-organ disorder 25.80 11.02 14 35044 1239 50568827
Swelling 25.53 11.02 64 34994 200808 50369258
No adverse event 25.08 11.02 65 34993 33513 50536553
Foetal hypokinesia 24.72 11.02 10 35048 453 50569613
Splenic injury 24.71 11.02 8 35050 189 50569877
Exposure via skin contact 24.67 11.02 8 35050 190 50569876
Wrong technique in product usage process 24.17 11.02 89 34969 55421 50514645
Nasopharyngitis 24.11 11.02 62 34996 192865 50377201
Euglycaemic diabetic ketoacidosis 23.94 11.02 18 35040 2801 50567265
Peripheral swelling 23.62 11.02 69 34989 205867 50364199
Sprue-like enteropathy 23.54 11.02 10 35048 513 50569553
Exposure via eye contact 22.33 11.02 4 35054 4 50570062
Renal dysplasia 22.22 11.02 7 35051 151 50569915
Product use in unapproved indication 21.76 11.02 29 35029 115790 50454276
Toxicity to various agents 21.71 11.02 75 34983 212424 50357642
Blood creatinine increased 21.46 11.02 107 34951 76053 50494013
Urinary tract infection 21.26 11.02 243 34815 223777 50346289
Diabetes mellitus 20.84 11.02 78 34980 48955 50521111
Hypochromasia 20.67 11.02 8 35050 322 50569744
Antibody test negative 20.65 11.02 5 35053 38 50570028
Product dispensing error 20.56 11.02 28 35030 8863 50561203
Visual acuity reduced 20.50 11.02 44 35014 20095 50549971
Cardiac arrest 20.45 11.02 113 34945 83538 50486528
Hypoglycaemia unawareness 20.27 11.02 6 35052 104 50569962
Diabetic foot 19.83 11.02 12 35046 1306 50568760
Hypersensitivity 19.34 11.02 80 34978 215081 50354985
Hepatic function abnormal 19.22 11.02 58 35000 32623 50537443
Treatment noncompliance 19.16 11.02 55 35003 30095 50539971
Irritable bowel syndrome 18.96 11.02 6 35052 51435 50518631
Rubella antibody negative 18.83 11.02 3 35055 0 50570066
Diabetic metabolic decompensation 18.55 11.02 12 35046 1468 50568598
Sepsis 18.38 11.02 156 34902 132769 50437297
Hypoglycaemia neonatal 18.29 11.02 10 35048 898 50569168
Helicobacter infection 17.96 11.02 6 35052 49696 50520370
Respiratory disorder neonatal 17.96 11.02 10 35048 931 50569135
Diabetic coma 17.79 11.02 9 35049 690 50569376
Hyperchloraemia 17.76 11.02 9 35049 692 50569374
Folliculitis 17.57 11.02 3 35055 39222 50530844
Rabbit syndrome 17.39 11.02 7 35051 313 50569753
Gastrointestinal disorder 17.39 11.02 24 35034 94432 50475634
Polyhydramnios 17.35 11.02 13 35045 2012 50568054
Migraine 17.27 11.02 16 35042 75264 50494802
Diabetic nephropathy 17.13 11.02 11 35047 1328 50568738
Cardiac failure 16.81 11.02 100 34958 75940 50494126
Neutropenia 16.65 11.02 50 35008 147915 50422151
Anisocytosis 16.32 11.02 8 35050 573 50569493
Disseminated intravascular coagulation 15.82 11.02 36 35022 17099 50552967
Bicuspid aortic valve 15.78 11.02 5 35053 110 50569956
Congenital hydronephrosis 15.65 11.02 7 35051 407 50569659
Thirst 15.41 11.02 27 35031 10623 50559443
Renal injury 15.38 11.02 24 35034 8587 50561479
Accidental underdose 15.38 11.02 8 35050 650 50569416
Fall 15.33 11.02 321 34737 334611 50235455
Acidosis 14.89 11.02 26 35032 10201 50559865
Conjoined twins 14.79 11.02 6 35052 274 50569792
Paraesthesia 14.73 11.02 39 35019 120204 50449862
Urine output decreased 14.54 11.02 26 35032 10395 50559671
Renal impairment 14.54 11.02 96 34962 75565 50494501
Insomnia 14.50 11.02 67 34991 174798 50395268
Agitation neonatal 14.35 11.02 7 35051 496 50569570
Cellulitis 14.32 11.02 91 34967 70707 50499359
Macular oedema 14.22 11.02 15 35043 3639 50566427
Premature baby 14.21 11.02 36 35022 18301 50551765
Multiple sclerosis relapse 14.16 11.02 6 35052 42958 50527108
Macrosomia 13.99 11.02 4 35054 61 50570005
Blood creatine phosphokinase increased 13.85 11.02 45 35013 26322 50543744
Congenital aortic valve stenosis 13.53 11.02 4 35054 69 50569997
Bradycardia neonatal 13.50 11.02 8 35050 838 50569228
Ill-defined disorder 13.28 11.02 11 35047 54643 50515423
Haemodialysis 13.15 11.02 22 35036 8340 50561726
Loss of consciousness 13.14 11.02 120 34938 104233 50465833
Intercepted product selection error 13.00 11.02 3 35055 18 50570048
Hyperglycaemic hyperosmolar nonketotic syndrome 12.97 11.02 7 35051 613 50569453
Acute myocardial infarction 12.80 11.02 47 35011 29226 50540840
Intentional product use issue 12.75 11.02 21 35037 76897 50493169
Loss of personal independence in daily activities 12.69 11.02 18 35040 70032 50500034
Arthralgia 12.61 11.02 221 34837 438481 50131585
Pre-eclampsia 12.44 11.02 21 35037 8023 50562043
Corynebacterium infection 12.42 11.02 6 35052 416 50569650
Cerebral infarction 12.38 11.02 38 35020 21566 50548500
Protein deficiency 12.35 11.02 5 35053 227 50569839
Blood urea increased 12.16 11.02 40 35018 23545 50546521
Urogenital haemorrhage 12.11 11.02 5 35053 239 50569827
Renal disorder 11.89 11.02 44 35014 27461 50542605
Hepatosplenic candidiasis 11.76 11.02 5 35053 257 50569809
Toe amputation 11.70 11.02 10 35048 1867 50568199
Shock hypoglycaemic 11.64 11.02 4 35054 114 50569952
Red blood cell sedimentation rate increased 11.64 11.02 3 35055 29413 50540653
General physical health deterioration 11.53 11.02 150 34908 142284 50427782
Diaphragmalgia 11.51 11.02 4 35054 118 50569948
Hypoglycaemic encephalopathy 11.48 11.02 5 35053 273 50569793
Blindness unilateral 11.38 11.02 16 35042 5219 50564847
Congenital mitral valve incompetence 11.16 11.02 3 35055 36 50570030
Arrhythmia 11.12 11.02 49 35009 33083 50536983
Angina unstable 11.03 11.02 18 35040 6688 50563378

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 743.64 11.05 530 32112 47816 29494069
Blood glucose increased 720.50 11.05 563 32079 58421 29483464
Blood glucose decreased 274.05 11.05 169 32473 11900 29529985
Hyperglycaemia 198.57 11.05 216 32426 34071 29507814
Diabetes mellitus inadequate control 158.90 11.05 121 32521 12013 29529872
Glycosylated haemoglobin increased 136.83 11.05 100 32542 9326 29532559
Anti-insulin antibody positive 123.14 11.05 31 32611 165 29541720
Diabetic ketoacidosis 119.71 11.05 116 32526 15957 29525928
Blood glucose fluctuation 115.18 11.05 63 32579 3534 29538351
Completed suicide 76.88 11.05 6 32636 90240 29451645
Hypoglycaemic unconsciousness 70.97 11.05 28 32614 735 29541150
Incorrect dose administered 68.22 11.05 127 32515 32857 29509028
Drug abuse 63.54 11.05 7 32635 79876 29462009
Blood glucose abnormal 62.83 11.05 49 32593 5034 29536851
Diabetic retinopathy 62.45 11.05 32 32610 1570 29540315
Toxicity to various agents 61.10 11.05 61 32581 173600 29368285
Anti-insulin antibody 53.66 11.05 11 32631 17 29541868
Anti-insulin antibody increased 47.49 11.05 12 32630 65 29541820
Hypoglycaemic coma 45.81 11.05 29 32613 2134 29539751
Wrong product administered 44.08 11.05 38 32604 4493 29537392
Alveolar lung disease 43.15 11.05 16 32626 353 29541532
Hypoglycaemia unawareness 43.03 11.05 12 32630 100 29541785
Off label use 41.55 11.05 181 32461 300619 29241266
Product storage error 41.36 11.05 43 32599 6427 29535458
Pulmonary interstitial emphysema syndrome 39.52 11.05 16 32626 450 29541435
Hypoglycaemic encephalopathy 39.31 11.05 14 32628 274 29541611
Hypoglycaemic seizure 38.35 11.05 14 32628 295 29541590
Blindness 37.93 11.05 56 32586 11967 29529918
Diabetic neuropathy 37.58 11.05 32 32610 3721 29538164
Drug interaction 37.15 11.05 104 32538 197281 29344604
Clear cell renal cell carcinoma 33.11 11.05 18 32624 997 29540888
Diabetic metabolic decompensation 32.55 11.05 20 32622 1396 29540489
Product complaint 31.15 11.05 34 32608 5371 29536514
Insulin resistance 30.94 11.05 14 32628 520 29541365
Product prescribing error 28.51 11.05 62 32580 17914 29523971
Diabetes mellitus 27.86 11.05 102 32540 39729 29502156
Diabetic nephropathy 27.25 11.05 20 32622 1875 29540010
Peripheral arterial occlusive disease 25.95 11.05 30 32612 5046 29536839
Diffuse alveolar damage 25.91 11.05 20 32622 2023 29539862
Hypoaldosteronism 25.57 11.05 9 32633 170 29541715
Cardiac failure congestive 24.82 11.05 157 32485 76424 29465461
Toxic epidermal necrolysis 24.78 11.05 59 32583 18094 29523791
Acute myocardial infarction 24.34 11.05 112 32530 48326 29493559
Infusion site induration 24.17 11.05 9 32633 201 29541684
Product dispensing error 24.10 11.05 30 32612 5450 29536435
Mumps antibody test negative 23.24 11.05 4 32638 0 29541885
Joint swelling 23.11 11.05 13 32629 49617 29492268
Finnegan score increased 22.14 11.05 5 32637 15 29541870
Eosinophilic pneumonia 22.04 11.05 21 32621 2825 29539060
Agitation neonatal 21.97 11.05 14 32628 1042 29540843
Gangrene 21.68 11.05 25 32617 4193 29537692
Angina pectoris 20.91 11.05 73 32569 27777 29514108
Toe amputation 20.81 11.05 18 32624 2137 29539748
Infant irritability 20.46 11.05 5 32637 23 29541862
Drug ineffective 20.25 11.05 281 32361 362889 29178996
Cardiac failure 20.05 11.05 153 32489 79134 29462751
Diabetic complication 19.55 11.05 11 32631 652 29541233
Neonatal hypoxia 18.95 11.05 9 32633 374 29541511
Urethral cancer 18.82 11.05 5 32637 34 29541851
Sepsis 18.71 11.05 240 32402 142442 29399443
Wrong technique in product usage process 18.32 11.05 76 32566 31352 29510533
Bronchopneumopathy 18.32 11.05 9 32633 403 29541482
Treatment failure 18.19 11.05 9 32633 36930 29504955
No adverse event 17.89 11.05 51 32591 17427 29524458
Type 1 diabetes mellitus 17.73 11.05 21 32621 3623 29538262
General physical health deterioration 17.50 11.05 182 32460 102675 29439210
Renal failure 17.49 11.05 204 32438 118395 29423490
Rubella antibody negative 17.43 11.05 3 32639 0 29541885
Vaccination site erythema 17.43 11.05 3 32639 0 29541885
Measles antibody negative 17.43 11.05 3 32639 0 29541885
Myocardial infarction 17.30 11.05 192 32450 110104 29431781
Hyperlipidaemia 17.27 11.05 41 32601 12549 29529336
Blood urea increased 17.20 11.05 69 32573 28043 29513842
Hepatic function abnormal 17.00 11.05 87 32555 39172 29502713
Glycosylated haemoglobin decreased 16.79 11.05 8 32634 335 29541550
Diabetic foot 16.50 11.05 16 32626 2200 29539685
Agitated depression 16.36 11.05 7 32635 227 29541658
Hepatic encephalopathy 16.34 11.05 41 32601 12994 29528891
Selective eating disorder 16.28 11.05 14 32628 1649 29540236
Lymphangitis 16.14 11.05 9 32633 524 29541361
Neutropenia 15.91 11.05 83 32559 131628 29410257
Product monitoring error 15.87 11.05 17 32625 2628 29539257
Rheumatoid arthritis 15.58 11.05 8 32634 32144 29509741
Death 15.56 11.05 275 32367 341809 29200076
Diabetic coma 15.39 11.05 10 32632 770 29541115
Neuropathic arthropathy 15.22 11.05 6 32636 157 29541728
Ketosis 15.20 11.05 8 32634 415 29541470
Visual impairment 15.15 11.05 69 32573 29639 29512246
Somogyi phenomenon 14.89 11.05 3 32639 4 29541881
Product use in unapproved indication 14.71 11.05 48 32594 86827 29455058
Leishmaniasis 14.62 11.05 7 32635 296 29541589
Internal haemorrhage 14.51 11.05 21 32621 4406 29537479
Dysphagia 14.41 11.05 24 32618 54902 29486983
Diabetic hyperglycaemic coma 14.27 11.05 4 32638 34 29541851
Microalbuminuria 14.26 11.05 9 32633 659 29541226
Aggression 14.25 11.05 11 32631 35530 29506355
Meningocele 14.17 11.05 4 32638 35 29541850
Wound 14.14 11.05 37 32605 12026 29529859
Coronary artery disease 13.94 11.05 90 32552 44100 29497785
Oedema peripheral 13.90 11.05 175 32467 103382 29438503
Visual acuity reduced 13.88 11.05 42 32600 14834 29527051
Cutaneous amyloidosis 13.88 11.05 4 32638 38 29541847
Liver disorder 13.81 11.05 64 32578 27685 29514200
Mucosal inflammation 13.69 11.05 9 32633 31586 29510299
Floppy infant 13.58 11.05 5 32637 108 29541777
Renal cell carcinoma 13.57 11.05 21 32621 4675 29537210
Intra-abdominal haemorrhage 13.53 11.05 14 32628 2081 29539804
Acute kidney injury 13.33 11.05 385 32257 264882 29277003
Spermatic cord disorder 13.28 11.05 3 32639 9 29541876
Congenital pulmonary hypertension 13.03 11.05 4 32638 48 29541837
Lymphoproliferative disorder 13.03 11.05 15 32627 2512 29539373
Overdose 12.90 11.05 45 32597 79774 29462111
Streptococcal infection 12.87 11.05 20 32622 4468 29537417
Antibody test negative 12.82 11.05 3 32639 11 29541874
Post thrombotic syndrome 12.72 11.05 5 32637 130 29541755
Impaired insulin secretion 12.62 11.05 3 32639 12 29541873
Hyperglycaemic hyperosmolar nonketotic syndrome 12.55 11.05 10 32632 1060 29540825
Necrosis 12.49 11.05 21 32621 5009 29536876
Coombs negative haemolytic anaemia 12.05 11.05 5 32637 150 29541735
Pelvic abscess 11.88 11.05 9 32633 885 29541000
Hyperinsulinaemia 11.81 11.05 4 32638 67 29541818
Disease progression 11.42 11.05 49 32593 81867 29460018
Disseminated intravascular coagulation 11.40 11.05 48 32594 19932 29521953
Dyspnoea 11.07 11.05 453 32189 326279 29215606

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1335.31 10.51 869 53316 89023 64355524
Blood glucose increased 811.37 10.51 666 53519 97407 64347140
Hyperglycaemia 423.75 10.51 375 53810 60593 64383954
Blood glucose decreased 373.21 10.51 236 53949 22887 64421660
Diabetes mellitus inadequate control 300.79 10.51 200 53985 21121 64423426
Diabetic ketoacidosis 242.75 10.51 201 53984 29644 64414903
Glycosylated haemoglobin increased 227.71 10.51 151 54034 15868 64428679
Blood glucose fluctuation 210.62 10.51 102 54083 5853 64438694
Anti-insulin antibody positive 195.81 10.51 46 54139 241 64444306
Completed suicide 149.46 10.51 10 54175 224404 64220143
Hypoglycaemic coma 138.58 10.51 69 54116 4205 64440342
Diabetic retinopathy 129.51 10.51 58 54127 2781 64441766
No adverse event 97.24 10.51 120 54065 28441 64416106
Off label use 95.27 10.51 248 53937 632558 63811989
Anti-insulin antibody increased 91.05 10.51 21 54164 100 64444447
Anti-insulin antibody 83.85 10.51 18 54167 57 64444490
Drug abuse 82.25 10.51 8 54177 132366 64312181
Product complaint 81.88 10.51 73 54112 11881 64432666
Joint swelling 76.33 10.51 43 54142 215339 64229208
Drug ineffective 75.61 10.51 407 53778 839840 63604707
Product prescribing error 74.77 10.51 118 54067 35151 64409396
Toxicity to various agents 74.56 10.51 119 54066 363394 64081153
Insulin resistance 71.87 10.51 29 54156 1071 64443476
Hypoglycaemic unconsciousness 71.34 10.51 29 54156 1092 64443455
Wrong product administered 71.23 10.51 56 54129 7664 64436883
Cardiac failure congestive 70.84 10.51 256 53929 130324 64314223
Diabetic neuropathy 70.54 10.51 49 54136 5552 64438995
Toothache 70.42 10.51 80 54105 17379 64427168
Renal failure 68.30 10.51 318 53867 181370 64263177
Blood glucose abnormal 68.25 10.51 58 54127 8855 64435692
Pharyngitis 68.06 10.51 82 54103 18957 64425590
Acute kidney injury 67.74 10.51 624 53561 448616 63995931
Ketoacidosis 65.96 10.51 51 54134 6812 64437735
Rheumatoid arthritis 65.47 10.51 28 54157 164266 64280281
Treatment failure 65.37 10.51 10 54175 116806 64327741
Hyperkalaemia 65.14 10.51 210 53975 100919 64343628
Hypoglycaemic seizure 63.44 10.51 24 54161 744 64443803
Drug intolerance 61.77 10.51 41 54144 187951 64256596
Myocardial infarction 57.79 10.51 284 53901 165537 64279010
Diabetic metabolic decompensation 52.04 10.51 31 54154 2697 64441850
Product storage error 50.31 10.51 59 54126 13259 64431288
Coronary artery disease 47.86 10.51 135 54050 60298 64384249
Alopecia 46.96 10.51 42 54143 165648 64278899
Acute myocardial infarction 46.91 10.51 147 54038 69571 64374976
Infusion related reaction 46.24 10.51 42 54143 164425 64280122
Systemic lupus erythematosus 44.92 10.51 6 54179 77606 64366941
Pulmonary interstitial emphysema syndrome 43.86 10.51 16 54169 447 64444100
Pain 43.80 10.51 279 53906 553232 63891315
Glossodynia 42.69 10.51 3 54182 64693 64379854
Increased insulin requirement 41.89 10.51 12 54173 150 64444397
Alveolar lung disease 41.55 10.51 16 54169 521 64444026
Sepsis 40.91 10.51 332 53853 230009 64214538
Hypoglycaemia unawareness 40.77 10.51 12 54173 166 64444381
Fatigue 40.60 10.51 418 53767 748312 63696235
Arthropathy 40.23 10.51 26 54159 120941 64323606
Diabetic nephropathy 40.10 10.51 26 54159 2628 64441919
Gait inability 39.97 10.51 101 54084 42267 64402280
Hypoglycaemic encephalopathy 39.52 10.51 16 54169 596 64443951
Therapeutic product effect decreased 39.46 10.51 24 54161 115327 64329220
Diabetes mellitus 38.31 10.51 133 54052 66341 64378206
Blood creatinine increased 38.02 10.51 219 53966 135563 64308984
Musculoskeletal stiffness 37.66 10.51 29 54156 123177 64321370
Medication error 36.08 10.51 108 54077 49858 64394689
Cerebrovascular accident 36.00 10.51 218 53967 137365 64307182
Pericarditis 35.78 10.51 5 54180 62511 64382036
Sinusitis 35.66 10.51 42 54143 145886 64298661
Therapeutic product effect incomplete 34.74 10.51 22 54163 103460 64341087
Abdominal discomfort 34.27 10.51 63 54122 182259 64262288
Hepatic function abnormal 33.09 10.51 124 54061 64189 64380358
General physical health deterioration 32.76 10.51 288 53897 204137 64240410
Cardiac failure 31.06 10.51 204 53981 132169 64312378
Arthralgia 29.53 10.51 234 53951 442026 64002521
Chronic kidney disease 29.24 10.51 111 54074 57808 64386739
Central nervous system injury 29.20 10.51 9 54176 147 64444400
Expired product administered 28.61 10.51 30 54155 5957 64438590
Eye haemorrhage 28.25 10.51 35 54150 8325 64436222
Blood urea increased 27.79 10.51 91 54094 44062 64400485
Contraindicated product administered 27.47 10.51 30 54155 107799 64336748
Product use in unapproved indication 27.38 10.51 68 54117 176550 64267997
Diabetic coma 27.34 10.51 15 54170 1116 64443431
Peripheral swelling 26.93 10.51 88 54097 209065 64235482
Peripheral arterial occlusive disease 26.47 10.51 31 54154 6956 64437591
Type 1 diabetes mellitus 26.22 10.51 28 54157 5677 64438870
Retinopathy 25.97 10.51 22 54163 3343 64441204
Hypersensitivity 25.75 10.51 82 54103 196370 64248177
Clear cell renal cell carcinoma 24.98 10.51 18 54167 2161 64442386
Angina pectoris 24.94 10.51 89 54096 44992 64399555
Neutropenia 24.91 10.51 110 54075 239514 64205033
Toxic epidermal necrolysis 24.66 10.51 78 54107 37088 64407459
Blindness 24.54 10.51 56 54129 21963 64422584
Dehydration 23.97 10.51 283 53902 216480 64228067
Disseminated intravascular coagulation 23.43 10.51 70 54115 32278 64412269
Toe amputation 23.23 10.51 21 54164 3479 64441068
Diffuse alveolar damage 22.64 10.51 20 54165 3215 64441332
Cardiac arrest 22.60 10.51 213 53972 153851 64290696
Hypoaldosteronism 22.57 10.51 9 54176 322 64444225
Rash 22.37 10.51 262 53923 458287 63986260
Product use issue 22.29 10.51 60 54125 151655 64292892
Gangrene 22.08 10.51 29 54156 7309 64437238
Renal impairment 22.02 10.51 191 53994 134826 64309721
Diabetic foot 21.88 10.51 19 54166 2986 64441561
Diabetic complication 21.71 10.51 13 54172 1142 64443405
Oedema peripheral 21.69 10.51 271 53914 210046 64234501
Splenic injury 21.42 10.51 8 54177 239 64444308
Urine output decreased 20.71 10.51 44 54141 16448 64428099
Hepatic encephalopathy 20.69 10.51 51 54134 21015 64423532
Acidosis 20.66 10.51 46 54139 17749 64426798
Bronchopneumopathy 20.49 10.51 10 54175 583 64443964
Discomfort 20.05 10.51 23 54162 80855 64363692
Helicobacter infection 19.89 10.51 4 54181 38358 64406189
Nasopharyngitis 19.77 10.51 91 54094 195982 64248565
Intentional product use issue 19.70 10.51 31 54154 95333 64349214
Cerebral infarction 19.36 10.51 77 54108 40967 64403580
Hyperglycaemic hyperosmolar nonketotic syndrome 19.25 10.51 14 54171 1705 64442842
Exposure during pregnancy 19 10.51 121 54064 77554 64366993
Gastrointestinal disorder 18.69 10.51 29 54156 89680 64354867
Ketosis 18.63 10.51 11 54174 942 64443605
Serotonin syndrome 18.57 10.51 5 54180 39277 64405270
Urethral cancer 18.56 10.51 5 54180 49 64444498
Treatment noncompliance 18.48 10.51 79 54106 43403 64401144
Lactic acidosis 18.46 10.51 101 54084 61309 64383238
Paraesthesia 18.43 10.51 55 54130 134467 64310080
Product administration error 18.32 10.51 58 54127 27585 64416962
Multi-organ disorder 18.06 10.51 15 54170 2218 64442329
Hyperlipidaemia 17.86 10.51 51 54134 22925 64421622
Shock hypoglycaemic 17.76 10.51 7 54178 243 64444304
Incorrect dose administered 17.64 10.51 99 54086 60666 64383881
Glycosylated haemoglobin decreased 17.22 10.51 9 54176 607 64443940
Drug interaction 17.21 10.51 208 53977 361875 64082672
Renal disorder 17.21 10.51 67 54118 35298 64409249
Intestinal ischaemia 17.10 10.51 33 54152 11516 64433031
Renal injury 16.93 10.51 39 54146 15390 64429157
Eosinophilic pneumonia 16.83 10.51 20 54165 4557 64439990
Hypochromasia 16.64 10.51 9 54176 651 64443896
Agitated depression 16.54 10.51 7 54178 292 64444255
Influenza 16.51 10.51 41 54144 106490 64338057
Hepatic enzyme increased 16.49 10.51 55 54130 129888 64314659
Mucosal inflammation 16.39 10.51 17 54168 62567 64381980
Multiple sclerosis relapse 16.39 10.51 7 54178 41128 64403419
Headache 16.11 10.51 331 53854 529136 63915411
Flushing 15.84 10.51 26 54159 78622 64365925
Thirst 15.81 10.51 36 54149 14101 64430446
Multiple organ dysfunction syndrome 15.77 10.51 142 54043 101271 64343276
Drug resistance 15.62 10.51 5 54180 35097 64409450
Rabbit syndrome 15.52 10.51 7 54178 341 64444206
Osteonecrosis of jaw 15.51 10.51 7 54178 39818 64404729
Leishmaniasis 15.50 10.51 7 54178 342 64444205
Sprue-like enteropathy 15.35 10.51 10 54175 1019 64443528
Arrhythmia 15.20 10.51 86 54099 52858 64391689
Infusion site induration 14.69 10.51 9 54176 824 64443723
Ischaemic cardiomyopathy 14.65 10.51 23 54162 6815 64437732
Somogyi phenomenon 14.36 10.51 3 54182 8 64444539
Cutaneous amyloidosis 14.35 10.51 4 54181 45 64444502
Migraine 14.30 10.51 19 54166 62658 64381889
Anti-GAD antibody positive 14.19 10.51 4 54181 47 64444500
Necrosis 14.18 10.51 25 54160 8146 64436401
Cellulitis 13.98 10.51 130 54055 93527 64351020
Renal cell carcinoma 13.74 10.51 21 54164 6083 64438464
Neck pain 13.69 10.51 19 54166 61514 64383033
Hyperchloraemia 13.36 10.51 9 54176 970 64443577
Overdose 13.31 10.51 79 54106 159487 64285060
Muscle injury 13.21 10.51 3 54182 26434 64418113
Pneumonia aspiration 13.08 10.51 90 54095 59181 64385366
Swelling 13.00 10.51 80 54105 160138 64284409
Exposure via skin contact 12.98 10.51 5 54180 163 64444384
Localised infection 12.97 10.51 55 54130 30106 64414441
Fibromyalgia 12.83 10.51 7 54178 35724 64408823
Stomatitis 12.83 10.51 48 54137 109557 64334990
Neuropathic arthropathy 12.76 10.51 6 54179 322 64444225
Aggression 12.75 10.51 12 54173 46220 64398327
Decubitus ulcer 12.73 10.51 32 54153 13347 64431200
Internal haemorrhage 12.72 10.51 23 54162 7644 64436903
Insulin C-peptide decreased 12.61 10.51 4 54181 72 64444475
Product monitoring error 12.61 10.51 19 54166 5435 64439112
Mobility decreased 12.56 10.51 34 54151 85806 64358741
Peripheral ischaemia 12.48 10.51 24 54161 8354 64436193
Platelet count decreased 12.43 10.51 204 53981 167507 64277040
Peripheral vascular disorder 12.32 10.51 22 54163 7239 64437308
Cold sweat 12.29 10.51 36 54149 16419 64428128
Generalised oedema 12.25 10.51 42 54143 20811 64423736
Insulin autoimmune syndrome 12.24 10.51 6 54179 353 64444194
Intra-abdominal haemorrhage 12.23 10.51 16 54169 4015 64440532
Diabetic hyperglycaemic coma 12.22 10.51 4 54181 80 64444467
Psoriatic arthropathy 12.22 10.51 11 54174 43270 64401277
Product administered to patient of inappropriate age 12.05 10.51 17 54168 4584 64439963
Anisocytosis 11.93 10.51 8 54177 855 64443692
Loss of personal independence in daily activities 11.93 10.51 27 54158 72427 64372120
Altered state of consciousness 11.84 10.51 63 54122 37839 64406708
Blood creatine phosphokinase increased 11.81 10.51 87 54098 58471 64386076
Liver disorder 11.77 10.51 81 54104 53270 64391277
Bladder transitional cell carcinoma 11.72 10.51 12 54173 2318 64442229
Blood potassium increased 11.66 10.51 48 54137 25932 64418615
Diabetic ketoacidotic hyperglycaemic coma 11.57 10.51 5 54180 220 64444327
Pneumonia 11.43 10.51 577 53608 558999 63885548
Red blood cell sedimentation rate increased 11.39 10.51 6 54179 31229 64413318
Hyperlactacidaemia 11.38 10.51 17 54168 4827 64439720
Systemic infection 11.37 10.51 16 54169 4305 64440242
Euglycaemic diabetic ketoacidosis 11.32 10.51 18 54167 5392 64439155
Bladder cyst 11.27 10.51 4 54181 103 64444444
Hypoproteinaemia 11.17 10.51 14 54171 3368 64441179
Irritable bowel syndrome 11.15 10.51 9 54176 37360 64407187
Pulmonary oedema 11.14 10.51 108 54077 78566 64365981
Lymphangitis 11.01 10.51 9 54176 1302 64443245
COVID-19 treatment 11.00 10.51 6 54179 441 64444106
Fall 10.95 10.51 441 53744 416385 64028162
Corneal dystrophy 10.95 10.51 5 54180 251 64444296
Nasal congestion 10.86 10.51 21 54164 59637 64384910
Diabetic foot infection 10.73 10.51 7 54178 715 64443832
Cardiac failure acute 10.56 10.51 34 54151 16310 64428237
Injection site bruising 10.56 10.51 9 54176 36364 64408183

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AB01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, fast-acting
ATC A10AC01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, intermediate-acting
ATC A10AD01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
ATC A10AE01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
ATC A10AF01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for inhalation
FDA CS M0011417 Insulin
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
FDA EPC N0000175944 Insulin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Diabetes mellitus type 1 indication 46635009 DOID:9744
Overdose of beta-adrenergic blocking drug off-label use 296335002
Overdose of calcium-channel blockers off-label use 296355001




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Diabetes mellitus Indication
Dogs Diabetes mellitus Indication

🐶 Veterinary products

ProductApplicantIngredients
ProZinc Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Insulin receptor Kinase AGONIST DRUG LABEL DRUG LABEL
Tyrosine-protein kinase Lck Kinase IC50 4.74 CHEMBL
Insulin receptor Kinase IC50 8.71 CHEMBL

External reference:

IDSource
D03230 KEGG_DRUG
4020217 VUID
N0000179707 NUI
4017559 VANDF
4017569 VANDF
4019786 VANDF
4021631 VANDF
CHEBI:5931 CHEBI
CHEMBL1201631 ChEMBL_ID
CHEMBL1201539 ChEMBL_ID
CHEMBL1201540 ChEMBL_ID
CHEMBL1201627 ChEMBL_ID
CHEMBL1201641 ChEMBL_ID
CHEMBL1201644 ChEMBL_ID
CHEMBL1201543 ChEMBL_ID
5012 IUPHAR_LIGAND_ID
5186 INN_ID
DB00030 DRUGBANK_ID
1Y17CTI5SR UNII
118984375 PUBCHEM_CID
1372744 RXNORM
4885 MMSL
4886 MMSL
d00262 MMSL
d04369 MMSL
126210001 SNOMEDCT_US
39487003 SNOMEDCT_US
412222002 SNOMEDCT_US
412223007 SNOMEDCT_US
417423002 SNOMEDCT_US
420609005 SNOMEDCT_US
67866001 SNOMEDCT_US
96367001 SNOMEDCT_US
D007328 MESH_DESCRIPTOR_UI
C0795635 UMLSCUI
000869 NDDF
000870 NDDF
006518 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Humulin R HUMAN OTC DRUG LABEL 1 0002-8215 INJECTION, SOLUTION 100 [iU] PARENTERAL BLA 30 sections
Humulin N HUMAN OTC DRUG LABEL 1 0002-8315 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 30 sections
HumulinR U-500 HUMAN PRESCRIPTION DRUG LABEL 1 0002-8501 INJECTION, SOLUTION 500 [iU] SUBCUTANEOUS BLA 31 sections
Humulin 70/30 HUMAN OTC DRUG LABEL 1 0002-8715 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 30 sections
Humulin 70/30 KwikPen HUMAN OTC DRUG LABEL 1 0002-8803 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 30 sections
Humulin N HUMAN OTC DRUG LABEL 1 0002-8805 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 30 sections
HumulinR U-500 KwikPen HUMAN PRESCRIPTION DRUG LABEL 1 0002-8824 INJECTION, SOLUTION 500 [iU] SUBCUTANEOUS BLA 31 sections
NovolinR HUMAN OTC DRUG LABEL 1 0169-1833 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
NovolinN HUMAN OTC DRUG LABEL 1 0169-1834 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 24 sections
Novolin70/30 HUMAN OTC DRUG LABEL 1 0169-1837 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 25 sections
NovolinR HUMAN OTC DRUG LABEL 1 0169-3003 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
NovolinN HUMAN OTC DRUG LABEL 1 0169-3004 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 24 sections
Novolin70/30 HUMAN OTC DRUG LABEL 1 0169-3007 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 25 sections
MYXREDLIN HUMAN PRESCRIPTION DRUG LABEL 1 0338-0126 INJECTION, SOLUTION 1 [iU] INTRAVENOUS BLA 25 sections
MYXREDLIN HUMAN PRESCRIPTION DRUG LABEL 1 0338-0126 INJECTION, SOLUTION 1 [iU] INTRAVENOUS BLA 25 sections
Afrezza HUMAN PRESCRIPTION DRUG LABEL 1 47918-874 POWDER, METERED 4 1 RESPIRATORY (INHALATION) BLA 26 sections
Afrezza HUMAN PRESCRIPTION DRUG LABEL 1 47918-878 POWDER, METERED 8 1 RESPIRATORY (INHALATION) BLA 26 sections
Afrezza HUMAN PRESCRIPTION DRUG LABEL 1 47918-891 POWDER, METERED 12 1 RESPIRATORY (INHALATION) BLA 26 sections
Humulin N HUMAN OTC DRUG LABEL 1 50090-0352 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 31 sections
Novolin70/30 HUMAN OTC DRUG LABEL 1 50090-0403 INJECTION, SUSPENSION 100 [USPU] SUBCUTANEOUS NDA 12 sections
Humulin 70/30 HUMAN OTC DRUG LABEL 1 50090-0444 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 29 sections
NovolinR HUMAN OTC DRUG LABEL 1 50090-0497 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
NovolinN HUMAN OTC DRUG LABEL 1 50090-0498 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 24 sections
Humulin N HUMAN OTC DRUG LABEL 1 54868-1429 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 11 sections
Humalog 70/30 HUMAN OTC DRUG LABEL 1 54868-2746 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 9 sections
Novolin70/30 HUMAN OTC DRUG LABEL 1 54868-3474 INJECTION, SUSPENSION 100 [USPU] SUBCUTANEOUS NDA 13 sections
Humulin R HUMAN OTC DRUG LABEL 1 54868-3619 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS NDA 23 sections
Novolin R HUMAN OTC DRUG LABEL 1 64725-1833 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS NDA 26 sections
Novolin N HUMAN OTC DRUG LABEL 1 64725-1834 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 7 sections
Novolin 70/30 HUMAN OTC DRUG LABEL 1 64725-1837 INJECTION, SUSPENSION 100 [USPU] SUBCUTANEOUS NDA 11 sections